116 related articles for article (PubMed ID: 25656881)
21. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
Burtness B
Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
[TBL] [Abstract][Full Text] [Related]
22. Food and Drug Administration approval of cetuximab and a new KRAS genetic test for metastatic colorectal cancer: major advance but just the tip of the biomarker iceberg.
Lieberman R
Am J Ther; 2012 Nov; 19(6):395-6. PubMed ID: 23011178
[No Abstract] [Full Text] [Related]
23. The price tag on progress--chemotherapy for colorectal cancer.
Schrag D
N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
[No Abstract] [Full Text] [Related]
24. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
Shitara K; Yokota T; Takahari D; Shibata T; Ura T; Komatsu Y; Yuki S; Yoshida M; Takiuchi H; Utsunomiya S; Yatabe Y; Muro K
Jpn J Clin Oncol; 2010 Jul; 40(7):699-701. PubMed ID: 20304778
[TBL] [Abstract][Full Text] [Related]
25. Cetuximab plus chemotherapy as first-line treatment for metastatic colorectal cancer: effect of KRAS mutation on treatment efficacy in Taiwanese patients.
Chen MC; Chiang FF; Wang HM
Neoplasma; 2013; 60(5):561-7. PubMed ID: 23790176
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
27. [Application of monoclonal antibody in combination with irinotecan in the treatment of colorectal cancer].
Li J
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):796-7. PubMed ID: 17366800
[No Abstract] [Full Text] [Related]
28. New treatment options for colorectal cancer.
Erlichman C; Sargent DJ
N Engl J Med; 2004 Jul; 351(4):391-2. PubMed ID: 15269321
[No Abstract] [Full Text] [Related]
29. Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials.
Owzar K
J Clin Oncol; 2008 Mar; 26(9):1400-1. PubMed ID: 18349389
[No Abstract] [Full Text] [Related]
30. Molecular biomarker development for anti-EGFR therapy: moving beyond EGFR expression.
Chu E
Clin Colorectal Cancer; 2008 May; 7(3):162. PubMed ID: 18621632
[No Abstract] [Full Text] [Related]
31. ERBITUX as a single agent and in combination in colorectal carcinoma.
Expert Rev Anticancer Ther; 2002 Jun; 2(3):242. PubMed ID: 12113039
[No Abstract] [Full Text] [Related]
32. New issues on cetuximab mechanism of action in epidermal growth factor receptor-negative colorectal cancer: the role of vascular endothelial growth factor.
Vincenzi B; Santini D; Tonini G
J Clin Oncol; 2006 Apr; 24(12):1957; author reply 1957-8. PubMed ID: 16622275
[No Abstract] [Full Text] [Related]
33. [Use of anti-EGFR antibodies (cetuximab and panitumumab) in the treatment of metastatic colorectal cancer in KRAS wild type patients].
Smith D; Bosacki C; Merrouche Y
Bull Cancer; 2009 Dec; 96 Suppl():S31-40. PubMed ID: 20034868
[TBL] [Abstract][Full Text] [Related]
34. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Matsuoka A; Maeda O; Ando Y
N Engl J Med; 2015 Jan; 372(3):291. PubMed ID: 25587962
[No Abstract] [Full Text] [Related]
35. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Haines IE
N Engl J Med; 2015 Jan; 372(3):290-1. PubMed ID: 25587961
[No Abstract] [Full Text] [Related]
36. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Cremolini C; Loupakis F; Falcone A
N Engl J Med; 2015 Jan; 372(3):291-2. PubMed ID: 25587960
[No Abstract] [Full Text] [Related]
37. Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer: No Difference, but Not the Same.
Lieu CH; Messersmith WA
JAMA; 2017 Jun; 317(23):2376-2378. PubMed ID: 28632850
[No Abstract] [Full Text] [Related]
38. Cetuximab for resectable colorectal liver metastasis: new EPOC trial.
Hasegawa K; Oba M; Kokudo N
Lancet Oncol; 2014 Jul; 15(8):e305-6. PubMed ID: 24988931
[No Abstract] [Full Text] [Related]
39. Response phenotype as a predictive biomarker to guide treatment with targeted therapies.
Oxnard GR; Schwartz LH
J Clin Oncol; 2013 Oct; 31(30):3739-41. PubMed ID: 24043750
[No Abstract] [Full Text] [Related]
40. Chemotherapy and immunotherapy in metastatic colorectal cancer.
Pohlmann PR; Mernaugh RL; Goff LW
N Engl J Med; 2009 May; 360(20):2134; author reply 2135-6. PubMed ID: 19439750
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
